Wellington Management Group
ASND icon

Wellington Management Group’s Ascendis Pharma A/S ASND Stock Holding History

Wellington Management Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$402M Sell
1,757,633
-5,088
-0.3% -$1.14M 0.08% 235
2025
Q4 		$376M Sell
1,762,721
-36,210
-2% -$7.48M 0.07% 251
2025
Q3 		$358M Buy
1,798,931
+880,836
+96% +$164M 0.06% 268
2025
Q2 		$158M Buy
918,095
+330,332
+56% +$53.8M 0.03% 413
2025
Q1 		$91.6M Sell
587,763
-116,412
-17% -$16.6M 0.02% 526
2024
Q4 		$96.9M Sell
704,175
-557,305
-44% -$73.3M 0.02% 537
2024
Q3 		$188M Sell
1,261,480
-1,351,376
-52% -$182M 0.03% 408
2024
Q2 		$356M Sell
2,612,856
-133,016
-5% -$18.1M 0.06% 259
2024
Q1 		$415M Sell
2,745,872
-502,421
-15% -$71.7M 0.07% 252
2023
Q4 		$409M Sell
3,248,293
-28,879
-0.9% -$2.88M 0.08% 246
2023
Q3 		$307M Buy
3,277,172
+128,272
+4% +$12M 0.06% 283
2023
Q2 		$281M Buy
3,148,900
+215,108
+7% +$18.7M 0.05% 321
2023
Q1 		$315M Sell
2,933,792
-119,813
-4% -$13.7M 0.06% 287
2022
Q4 		$373M Sell
3,053,605
-618,621
-17% -$71.8M 0.07% 252
2022
Q3 		$379M Buy
3,672,226
+123,089
+3% +$11.7M 0.08% 235
2022
Q2 		$330M Sell
3,549,137
-1,116,442
-24% -$105M 0.07% 261
2022
Q1 		$548M Buy
4,665,579
+594,855
+15% +$68.9M 0.09% 210
2021
Q4 		$548M Buy
4,070,724
+125,480
+3% +$18.7M 0.09% 221
2021
Q3 		$629M Buy
3,945,244
+510,971
+15% +$69.9M 0.11% 191
2021
Q2 		$452M Sell
3,434,273
-58,060
-2% -$7.74M 0.08% 249
2021
Q1 		$450M Buy
3,492,333
+90,775
+3% +$13.8M 0.08% 241
2020
Q4 		$567M Buy
3,401,558
+149,797
+5% +$24.8M 0.1% 198
2020
Q3 		$502M Buy
3,251,761
+1,465,470
+82% +$211M 0.1% 183
2020
Q2 		$264M Buy
1,786,291
+116,145
+7% +$15.9M 0.06% 282
2020
Q1 		$188M Sell
1,670,146
-47,189
-3% -$6.13M 0.05% 314
2019
Q4 		$239M Buy
1,717,335
+923,269
+116% +$103M 0.05% 353
2019
Q3 		$76.5M Buy
794,066
+674,527
+564% +$75.2M 0.02% 606
2019
Q2 		$13.8M Buy
119,539
+9,962
+9% +$1.19M ﹤0.01% 1111
2019
Q1 		$12.9M Buy
109,577
+60,879
+125% +$5.33M ﹤0.01% 1137
2018
Q4 		$3.05M Buy
48,698
+5,467
+13% +$344K ﹤0.01% 1521
2018
Q3 		$3.06M Sell
43,231
-16,090
-27% -$1.11M ﹤0.01% 1596
2018
Q2 		$3.95M Buy
59,321
+41,786
+238% +$2.75M ﹤0.01% 1559
2018
Q1 		$1.15M Buy
+17,535
New +$986K ﹤0.01% 1872

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group's ASND Position: Q1 2026 in Review

Wellington Management Group reduced its Ascendis Pharma A/S (ASND) stake by 0.29% in Q1 2026, selling an estimated $1.14M and leaving 1,757,633 shares worth $402M. The position accounts for 0.08% of the portfolio, ranked #235.

Wellington Management Group first reported a position in ASND in Q1 2018 and has held it in 33 quarters since. The position peaked at $629M in Q3 2021. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Wellington Management Group held 1,757,633 shares of Ascendis Pharma A/S worth $402M as of Q1 2026.
  • Wellington Management Group sold 5,088 Ascendis Pharma A/S shares in Q1 2026, an estimated $1.14M.
  • Ascendis Pharma A/S made up 0.08% of Wellington Management Group's portfolio in Q1 2026, its #235 holding.
  • Wellington Management Group first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 33 quarters since.
  • Wellington Management Group's Ascendis Pharma A/S position peaked at $629M in Q3 2021.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.